176 related articles for article (PubMed ID: 33188425)
21. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
[TBL] [Abstract][Full Text] [Related]
22. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.
Herrick AL; Peytrignet S; Lunt M; Pan X; Hesselstrand R; Mouthon L; Silman AJ; Dinsdale G; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk MC; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jobanputra P; Jordan AC; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov NS; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman SM; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
Ann Rheum Dis; 2018 Apr; 77(4):563-570. PubMed ID: 29306872
[TBL] [Abstract][Full Text] [Related]
23. Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis.
Ostojic P; Damjanov N
Rheumatol Int; 2011 Aug; 31(8):1051-4. PubMed ID: 20309694
[TBL] [Abstract][Full Text] [Related]
24. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.
Takehara K; Ihn H; Sato S
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):151-6. PubMed ID: 23910617
[TBL] [Abstract][Full Text] [Related]
27. Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.
Utsunomiya A; Hasegawa M; Oyama N; Asano Y; Endo H; Fujimoto M; Goto D; Ishikawa O; Kawaguchi Y; Kuwana M; Ogawa F; Takahashi H; Tanaka S; Sato S; Takehara K; Ihn H
Mod Rheumatol; 2021 Jan; 31(1):162-170. PubMed ID: 32243215
[TBL] [Abstract][Full Text] [Related]
28. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
Dobrota R; Maurer B; Graf N; Jordan S; Mihai C; Kowal-Bielecka O; Allanore Y; Distler O;
Ann Rheum Dis; 2016 Oct; 75(10):1743-8. PubMed ID: 27016052
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.
Kaldas M; Khanna PP; Furst DE; Clements PJ; Kee Wong W; Seibold JR; Postlethwaite AE; Khanna D;
Rheumatology (Oxford); 2009 Sep; 48(9):1143-6. PubMed ID: 19605370
[TBL] [Abstract][Full Text] [Related]
30. Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
van Vollenhoven RF; Lee EB; Fallon L; Zwillich SH; Wilkinson B; Chapman D; DeMasi R; Keystone E
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):71-79. PubMed ID: 29696833
[TBL] [Abstract][Full Text] [Related]
31. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
[TBL] [Abstract][Full Text] [Related]
32. Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis.
Kersten BE; den Broeder N; van den Hoogen FHJ; Knaapen-Hans HAK; van den Ende CHM; Vonk MC
Rheumatology (Oxford); 2020 Jul; 59(7):1550-1555. PubMed ID: 31628802
[TBL] [Abstract][Full Text] [Related]
33. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
Chakravarty EF; Martyanov V; Fiorentino D; Wood TA; Haddon DJ; Jarrell JA; Utz PJ; Genovese MC; Whitfield ML; Chung L
Arthritis Res Ther; 2015 Jun; 17(1):159. PubMed ID: 26071192
[TBL] [Abstract][Full Text] [Related]
34. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
[TBL] [Abstract][Full Text] [Related]
35. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
36. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
[TBL] [Abstract][Full Text] [Related]
37. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
38. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
Mendoza FA; Nagle SJ; Lee JB; Jimenez SA
J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
[TBL] [Abstract][Full Text] [Related]
39. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.
Moghadam-Kia S; Charlton D; Aggarwal R; Oddis CV
Rheumatology (Oxford); 2019 Jun; 58(6):1011-1015. PubMed ID: 30608616
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic efficacy of combined glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis for skin sclerosis in diffuse systemic sclerosis.
Suga K; Yamashita H; Takahashi Y; Katagiri D; Hinoshita F; Kaneko H
Medicine (Baltimore); 2020 Mar; 99(10):e19301. PubMed ID: 32150064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
